Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3037% above fair value
$42.99−1.22 (-2.76%)
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
Arrowhead Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Arrowhead Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $723.37M, up 27.3% year over year. For fiscal 2025 it was $607.16M, up 20.0% from the year before. Over ten years it grew 29.1% a year on average. The highest annual figure on record is $607.16M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $607.16M | +20.0% |
| FY2024 | Sep 30, 2024 | $505.87M | +43.2% |
| FY2023 | Sep 30, 2023 | $353.19M | +18.8% |
| FY2022 | Sep 30, 2022 | $297.31M | +44.1% |
| FY2021 | Sep 30, 2021 | $206.34M | +60.1% |
| FY2020 | Sep 30, 2020 | $128.88M | +59.0% |
| FY2019 | Sep 30, 2019 | $81.05M | +53.0% |
| FY2018 | Sep 30, 2018 | $52.97M | +4.1% |
| FY2017 | Sep 30, 2017 | $50.90M | -18.1% |
| FY2016 | Sep 30, 2016 | $62.12M | +31.4% |
| FY2015 | Sep 30, 2015 | $47.27M | +104.3% |
| FY2014 | Sep 30, 2014 | $23.14M | +165.8% |
| FY2013 | Sep 30, 2013 | $8.71M | +61.5% |
| FY2012 | Sep 30, 2012 | $5.39M | +64.5% |
| FY2011 | Sep 30, 2011 | $3.28M | +518.9% |
| FY2010 | Sep 30, 2010 | $529.60K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $198.22M | +22.1% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $173.25M | +30.2% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $177.20M | +29.3% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $174.69M | +28.6% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $162.37M | +6.5% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $133.10M | +31.6% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $137.00M | +17.6% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $135.83M | +36.0% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $152.43M | +60.9% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $101.12M | +35.0% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $116.49M | +39.2% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $99.86M | +19.8% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $94.76M | +31.3% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $74.88M | -1.5% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $83.70M | +27.3% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $83.38M | +26.8% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $72.18M | +21.7% |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | $75.99M | +70.0% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $65.77M | +79.9% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $65.77M | +51.2% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $59.33M | +82.1% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $44.70M | +51.8% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $36.56M | +56.4% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $43.49M | +85.9% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $32.57M | +68.8% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $29.44M | +41.6% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $23.37M | +33.0% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $23.39M | +46.2% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $19.29M | +60.1% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $20.80M | +73.3% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $17.57M | +36.0% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $15.99M | +18.1% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $12.05M | +8.2% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $12.00M | +4.9% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $12.92M | +35.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $13.54M | -58.1% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $11.14M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $11.44M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $9.53M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $32.33M | – |
See a number that looks wrong?